Global Health & Medicine
Online ISSN : 2434-9194
Print ISSN : 2434-9186

この記事には本公開記事があります。本公開記事を参照してください。
引用する場合も本公開記事を引用してください。

Corticosteroid therapy for severe COVID-19 pneumonia: optimal dose and duration of administration
Wataru MatsudaTatsuya OkamotoTatsuki UemuraKentaro KobayashiRyo SasakiAkio Kimura
著者情報
ジャーナル フリー 早期公開

論文ID: 2020.01046

この記事には本公開記事があります。
詳細
抄録

Severe COVID-19 is associated with a hyperinflammatory state, and corticosteroid therapy may be effective. We review the recent literature and discuss the appropriate dose and duration of corticosteroid therapy. Low-dose corticosteroid therapy is often used to treat COVID-19. However, several doses of methylprednisolone (or prednisolone) have been attempted, ranging from about 40 mg/day to 2 mg/kg/day. Doses may need to be adjusted depending on severity. Corticosteroid therapy is generally administered for a short period over several days. However, COVID-19-induced respiratory failure is often prolonged, so longer administration may be considered. Careful monitoring for complications due to corticosteroid therapy is vital.

著者関連情報
© 2020 National Center for Global Health and Medicine
feedback
Top